Europe is stepping up its efforts to prepare for future health crises. A new parliamentary committee will look at how to make the most of the lessons learned from the coronavirus pandemic, while EU health ministers will next week discuss “vaccine solidarity” and the draft regulation on cross-border threats to health.
The European Parliament has named the members of a new EU committee set up to look at lessons learned from the COVID-19 pandemic and to make recommendations for future practice.
Areas of focus for the new body include vaccine procurement, manufacturing, the role of the pharmaceutical industry, access to vaccines...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
